The DOI matches its Crossref record; 186 of the 186 references it cites were found in a registry or an index.
Drug Resistance and the Solid Tumor Microenvironment
Abstract
Resistance of human tumors to anticancer drugs is most often ascribed to gene mutations, gene amplification, or epigenetic changes that influence the uptake, metabolism, or export of drugs from single cells. Another important yet little-appreciated cause of anticancer drug resistance is the limited ability of drugs to penetrate tumor tissue and to reach all of the tumor cells in a potentially lethal concentration. To reach all viable cells in the tumor, anticancer drugs must be delivered efficiently through the tumor vasculature, cross the vessel wall, and traverse the tumor tissue. In addition, heterogeneity within the tumor microenvironment leads to marked gradients in the rate of cell proliferation and to regions of hypoxia and acidity, all of which can influence the sensitivity of the tumor cells to drug treatment. In this review, we describe how the tumor microenvironment may be involved in the resistance of solid tumors to chemotherapy and discuss potential strategies to improve the effectiveness of drug treatment by modifying factors relating to the tumor microenvironment.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Similarly, agents like paclitaxel, which preferentially target rapidly dividing cells, exhibit reduced cytotoxicity in the low-proliferation zones of tumor cores [99,113].”
From Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis (2025) · cites this paper as [113]
In the citing paper
“This absence of gradient effectively inhibits transvascular convection and impedes the extravasation of large therapeutic molecules into the tumor parenchyma [113,152].”
From Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis (2025) · cites this paper as [113]
In the citing paper
“pH measurements within spheroid cores consistently range between 6.5 and 7.2, which closely mirrors the acidic pH observed in solid tumors [107,113].”
From Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis (2025) · cites this paper as [113]
In the citing paper
“These patterns arise from restricted diffusion of oxygen and metabolites toward the spheroid interior, recapitulating key features of avascular tumor regions [113,187].”
From Modeling Tumor Microenvironment Complexity In Vitro: Spheroids as Physiologically Relevant Tumor Models and Strategies for Their Analysis (2025) · cites this paper as [113]
In the citing paper
“The increased drug resistance in 3D culture can also be attributed to limited diffusion through the spheroid and to hypoxia, which has been shown to lead to the activation of genes involved in cell survival and drug sensitivity. 53”
From Three-dimensional cell culture systems and their applications in drug discovery and cell-based biosensors (2014) · cites this paper as [53]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(1909) · Journal of the American Medical Association · doi:10.1001/jama.1909.02550020033007 · Cited by 7,866
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
Jain, R. K. (2005) · Science · doi:10.1126/science.1104819 · Cited by 5,527
Tumour stem cells and drug resistance
Dean, M., Fojo, T., & Bates, S. (2005) · Nature reviews. Cancer · doi:10.1038/nrc1590 · Cited by 3,668
(1989) · PubMed · Cited by 3,343
Exploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
Drug penetration in solid tumours
Minchinton, A. I., & Tannock, I. F. (2006) · Nature reviews. Cancer · doi:10.1038/nrc1893 · Cited by 2,805
Self-citation
Research works printed but not linked: 44
- Teicher, 1990, Science, 247, 1457, 10.1126/science.2108497 · doi:10.1126/science.2108497 · Paper page
- Brekken, 2000, Anticancer Research, 20, 3503
- Netti, 2000, Cancer Research, 60, 2497
- Durand, 1986, JNCI Journal of the National Cancer Institute, 77, 247
- Jain, 1988, Cancer Research, 48, 2641
- Sevick, 1989, Cancer Research, 49, 3506
- Sevick, 1991, Cancer Research, 51, 2727
- Tannock, 1989, Cancer Research, 49, 4373
- Leu, 2000, Cancer Research, 60, 4324
- Milosevic, 1998, Cancer, 82, 2418, 10.1002/(SICI)1097-0142(19980615)82:12<2418::AID-CNCR16>3.0.CO;2-S · DOI
- Stohrer, 2000, Cancer Research, 60, 4251
- Evans, 2000, Cancer Research, 60, 2018
- Vaupel, 1989, Cancer Research, 49, 6449
- Tannock, 1978, Cancer treatment reports, 62, 1117
- Guo, 1998, Journal of cellular physiology, 175, 141, 10.1002/(SICI)1097-4652(199805)175:2<141::AID-JCP3>3.0.CO;2-O · doi:10.1002/(sici)1097-4652(199805)175:2<141::aid-jcp3>3.0.co;2-o
- Kinoshita, 2001, International journal of cancer. Journal international du cancer, 91, 322, 10.1002/1097-0215(200002)9999:9999<::AID-IJC1064>3.0.CO;2-P · doi:10.1002/1097-0215(200002)9999:9999<::aid-ijc1064>3.0.co;2-p
- Kondo, 2001, Cancer Research, 61, 7603
- Comerford, 2002, Cancer Research, 62, 3387
- Yun, 1995, Oncology research, 7, 583
- Ledoux, 2003, Cancer Research, 63, 7284
- Kennedy, 1987, Anti-cancer drug design, 2, 181
- Jain, 1990, Cancer Research, 50, 814s
- Netti, 1995, Cancer Research, 55, 5451
- Curti, 1993, Cancer Research, 53, 2204
- Boucher, 1990, Cancer Research, 50, 4478
- Fujimori, 1990, Journal of Nuclear Medicine, 31, 1191
- Juweid, 1992, Cancer Research, 52, 5144
- West, 1980, Cancer Research, 40, 3665
- Tannock, 2002, Clinical Cancer Research, 8, 878
- Lankelma, 1999, Clinical Cancer Research, 5, 1703
- Miyamoto, 2005, Oncology reports, 14, 1421
- Winkler, 2004, Cancer cell, 6, 553
- 2006, Cancer Research, 24, 11520
- Kristjansen, 1993, Cancer Research, 53, 4764
- Griffon-Etienne, 1999, Cancer Research, 59, 3776
- Rubin, 2000, International journal of cancer. Journal international du cancer, 86, 636, 10.1002/(SICI)1097-0215(20000601)86:5<636::AID-IJC6>3.0.CO;2-R · DOI
- Pietras, 2002, Cancer Research, 62, 5476
- Pietras, 2003, Clinical Cancer Research, 9, 3779
- Tunggal, 2000, International journal of cancer. Journal international du cancer, 86, 101, 10.1002/(SICI)1097-0215(20000401)86:1<101::AID-IJC16>3.0.CO;2-I · DOI
- Dalton, 1995, Cancer, 75, 815, 10.1002/1097-0142(19950201)75:3<815::AID-CNCR2820750311>3.0.CO;2-R · DOI
- Kozin, 2001, Cancer Research, 61, 4740
- Kontermann, 2006, Current opinion in molecular therapeutics, 8, 39
- Hicks, 2003, Cancer Research, 63, 5970
- Mose, 1964, Cancer Research, 24, 212
Cited by
Olive, K. P., Jacobetz, M. A., Davidson, C. J., Gopinathan, A., McIntyre, D., Honess, D., Madhu, B., Goldgraben, M. A., Caldwell, M. E., Allard, D., et al. (2009) · Science · doi:10.1126/science.1171362 · Cited by 3,170
Influence of tumour micro-environment heterogeneity on therapeutic response
Junttila, M. R., & de Sauvage, F. J. (2013) · Nature · doi:10.1038/nature12626 · Cited by 2,694
Edmondson, R., Broglie, J. J., Adcock, A. F., & Yang, L. (2014) · ASSAY and Drug Development Technologies · doi:10.1089/adt.2014.573 · Cited by 2,515
Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., & Hingorani, S. R. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.01.007 · Cited by 2,195
“Thus, although HA has been implicated in a variety of cell autonomous and noncell autonomous processes, its precise role(s) in therapeutic resistance of cancers has remained elusive and is likely context specific (reviewed in Toole and Slomiany, 2008; Trédan et al., 2007).”
BackgroundInfluentialTumor microenvironment and therapeutic response
Wu, T., & Dai, Y. (2017) · Cancer Letters · doi:10.1016/j.canlet.2016.01.043 · Cited by 1,802
Metadata
- Authors
- Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F.
- Affiliations
- Lyon 1 Université (FR)
- Venue
- JNCI Journal of the National Cancer Institute
- Publisher
- Oxford University Press (OUP)
- Published
- 2007-09-25
- Volume
- 99
- Issue
- 19
- Pages
- 1441-1454
- ISSN
- 0027-8874 (ISSN-L)
- 1460-2105
- OpenAlex
- W2165836181
- Semantic Scholar
- 08b1c43958dbb249104e14404ef6b266611e5d76
- Cited by
- 2,116
- References
- 185
- Citations by year
- 2026: 56 · 2025: 69 · 2024: 98 · 2023: 129 · 2022: 138 · 2021: 176 · 2020: 173 · 2019: 153 · 2018: 149 · 2017: 150 · 2016: 151 · 2015: 140 · 2014: 130 · 2013: 103 · 2012: 90
- FWCI
- 4.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- JNCI Journal of the National Cancer Institute (publishedVersion)
- PubMed (publishedVersion)
- HighWire Press Open Archive (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Medicine › Oncology › Drug Transport and Resistance Mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- drug resistance, solid tumors, tumor microenvironment, chemoresistance, tumor heterogeneity, tumor hypoxia, tumor acidosis, drug penetration, tumor vasculature, drug delivery
- MeSH terms
- Animals, Antineoplastic Agents, Humans, Microcirculation, Neoplasms, Cell Hypoxia, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Drug Resistance and the Solid Tumor Microenvironment. https://app.cochat.ai/papers/10.1093/jnci/djm135
- The paper
- Tredan, O., Galmarini, C. M., Patel, K., & Tannock, I. F. (2007). Drug Resistance and the Solid Tumor Microenvironment. JNCI Journal of the National Cancer Institute. https://doi.org/10.1093/jnci/djm135
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.